Richard Cline, MD
Nephrology · Murray, UTNPI 1245237080
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $306 and has fallen 59.7% since, to $123 in 2023. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.
Across 32 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$121
- Fresenius USA Marketing, Inc.$118
- AbbVie$112
- Amgen$82
- Boston Scientific$77
- GSK$45
- plus $226 from 11 others
What the payments were for
- Food & beverage$75597%
- Education$253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $121 |
| Fresenius USA Marketing, Inc. | 2 | $118 |
| AbbVie(2 entities) | 7 | $112 |
| Amgen | 2 | $82 |
| Boston Scientific | 4 | $77 |
| GSK | 1 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $29 |
| OPKO Pharmaceuticals, LLC | 1 | $25 |
| Travere Therapeutics, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$780 in reported general payments places this provider in the 45th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 15 | $59 |
| Atorvastatin Calcium | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Murray
- Anitha VijayanMurray$118K
- Vishnu ParvathareddyMurray$4K
- Bogdan AneaMurray$2K
- Mark KrausMurray$1K
- Sanjiv AnandSouth Salt Lake$144K
- Alfred CheungSalt Lake City$132K
- Donald KohanSalt Lake City$119K
- Fuad ShihabSalt Lake City$83K
- William BaragerProvo$13K
- Srinivasa BeddhuSalt Lake City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.